CANTON, Mich. (October 5, 2018) – MMS Holdings Inc. (MMS) – award-winning, data-focused CRO – announced today its renewed dedication to the local communities surrounding Detroit and Ann Arbor by allocating a substantial amount of colleague time to volunteer...

UNITED KINGDOM (August 23, 2018) – MMS Holdings Inc. (MMS) – an award-winning, global clinical research organization – announced today that it has won the award for Best Global Biotech CRO in the International Life Sciences Awards 2018 by Global Health & Pharma...

This Saturday, MMS is hosting their annual Scientific Symposium India at its Asian headquarters in Bangalore, India. RSVP now at: Asia@mmsholdings.com AGENDA 9:30am: Ice Breaker – Deepthi Rajan Morning Address – Uma Sharma, Ph.D. Morning Activity – Deepthi Rajan...

Canton, Mich. (July 10, 2018) – MMS Holdings Inc. (MMS) – a global, leading clinical research organization – announced today its integrated support for Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and...

Durham, N.C. (June 13, 2018) – MMS Holdings Inc. (MMS) – a leading global clinical research organization – announced today that Lisa James has joined as Director, Business Operations and Client Relations. James brings a depth of industry and business experience,...

Is among the lowest attrition rates in the pharmaceutical industry regionally Bangalore, India (June 7, 2018) – MMS Holdings Inc. (MMS) – a global, leading clinical research organization – announced today two major promotions at its Asia headquarters, including Dr....

Canton, Mich. and Findlay, Ohio (May 1, 2018) – MMS Holdings Inc. (MMS) – a global, leading clinical research organization – announced today that they have partnered with the University of Findlay to provide online medical writing and clinical trial disclosures...

Canton, Mich. (April 13, 2018) – MMS Holdings Inc. (MMS) – a global, leading clinical research organization – announced today that it has surpassed a training milestone, now with more than 700 training courses available in their learning management system. This...

MMS Holdings Inc. (MMS) announced today that it was selected by Paratek Pharmaceuticals, Inc., (NASDAQ: PRTK) to support the development of its U.S. new drug applications (NDAs) for omadacycline. Paratek is a biopharmaceutical company focused on the development and...